Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma

Published:2015-03-24 Issue:9 Volume:29 Page:1918-1927
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kikuchi S,Suzuki R,Ohguchi H,Yoshida Y,Lu D,Cottini F,Jakubikova J,Bianchi G,Harada T,Gorgun G,Tai Y-T,Richardson P G,Hideshima T,Anderson K C

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201583.pdf

Reference43 articles.

1. Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046–1060.

2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

3. Munshi NC, Anderson KC . New strategies in the treatment of multiple myeloma. Clin Cancer Res 2013; 19: 3337–3344.

4. Bolden JE, Peart MJ, Johnstone RW . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769–784.

5. Falkenberg KJ, Johnstone RW . Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13: 673–691.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting apoptotic pathways for cancer therapy;Journal of Clinical Investigation;2024-07-15

2. HDAC4 represses ER stress induced chondrocyte apoptosis by inhibiting ATF4 and attenuates cartilage degeneration in an osteoarthritis rat model;BMC Musculoskeletal Disorders;2024-06-15

3. Targeted therapy for multiple myeloma: an overview on CD138-based strategies;Frontiers in Oncology;2024-04-09

4. Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models;Molecular Oncology;2024-02-13

5. 5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib;European Journal of Medicinal Chemistry;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3